Andrew Davies, MRCP, PhD from University of Southampton, Southampton, UK describes the role and actions of the precision medicine for aggressive lymphoma (PMAL) consortium. Designed to be a collaboration between academia and industry, aims include optimizing diagnostic and stratification of patients with diffuse large B-Cell lymphoma (DLBCL). PMAL includes a network of individuals looking at transcriptome technology for use in DLBCL, optimizing signatures, identifying endotypes and mutation screening, among many other areas. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up